Catawba Capital Management VA Has $7.41 Million Stake in Becton Dickinson and Co (BDX)

Catawba Capital Management VA trimmed its holdings in Becton Dickinson and Co (NYSE:BDX) by 8.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 34,601 shares of the medical instruments supplier’s stock after selling 3,013 shares during the period. Becton Dickinson and comprises about 1.7% of Catawba Capital Management VA’s holdings, making the stock its 11th largest position. Catawba Capital Management VA’s holdings in Becton Dickinson and were worth $7,407,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in shares of Becton Dickinson and by 8.5% in the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after purchasing an additional 1,353,780 shares during the last quarter. State Street Corp raised its holdings in shares of Becton Dickinson and by 3.5% in the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after purchasing an additional 342,873 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Becton Dickinson and by 4.0% in the second quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock valued at $549,028,000 after purchasing an additional 106,966 shares during the last quarter. Fiera Capital Corp raised its holdings in shares of Becton Dickinson and by 7.1% in the second quarter. Fiera Capital Corp now owns 2,782,146 shares of the medical instruments supplier’s stock valued at $542,825,000 after purchasing an additional 183,372 shares during the last quarter. Finally, Fundsmith LLP raised its holdings in shares of Becton Dickinson and by 0.3% in the second quarter. Fundsmith LLP now owns 2,302,590 shares of the medical instruments supplier’s stock valued at $449,258,000 after purchasing an additional 5,977 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Becton Dickinson and Co (BDX) traded up $5.70 during midday trading on Friday, reaching $217.14. 2,020,503 shares of the company were exchanged, compared to its average volume of 1,690,000. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.54 and a quick ratio of 5.03. The stock has a market capitalization of $49,810.00, a P/E ratio of 165.76, a PEG ratio of 1.49 and a beta of 1.12. Becton Dickinson and Co has a 1-year low of $175.66 and a 1-year high of $248.39.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, topping analysts’ consensus estimates of $2.41 by $0.07. The firm had revenue of $3.08 billion during the quarter, compared to analyst estimates of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the business earned $2.33 earnings per share. research analysts predict that Becton Dickinson and Co will post 10.95 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be given a dividend of $0.75 per share. The ex-dividend date of this dividend is Thursday, March 8th. This represents a $3.00 dividend on an annualized basis and a yield of 1.38%. Becton Dickinson and’s dividend payout ratio is presently 229.01%.

Several brokerages have recently commented on BDX. Morgan Stanley increased their target price on shares of Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a report on Wednesday. Piper Jaffray Companies reiterated an “overweight” rating and issued a $260.00 target price (up previously from $223.00) on shares of Becton Dickinson and in a report on Tuesday, February 6th. Zacks Investment Research upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 price objective for the company in a report on Friday, January 19th. Bank of America restated a “buy” rating and set a $260.00 price objective on shares of Becton Dickinson and in a report on Friday, January 19th. Finally, Citigroup upgraded shares of Becton Dickinson and from a “sell” rating to a “neutral” rating in a report on Friday, January 5th. Four equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $237.27.

ILLEGAL ACTIVITY WARNING: “Catawba Capital Management VA Has $7.41 Million Stake in Becton Dickinson and Co (BDX)” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://ledgergazette.com/2018/02/12/becton-dickinson-and-co-bdx-shares-sold-by-catawba-capital-management-va.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply